2022 World Conference on Lung Cancer (ePosters)-EP16.01-024. Differential Efficacy of Combined GITR Co-stimulation with PD-1 Blockade in Preclinical Non-small Cell Lung Cancer Models

EP16.01-024. Differential Efficacy of Combined GITR Co-stimulation with PD-1 Blockade in Preclinical Non-small Cell Lung Cancer Models

Back to course

Pdf Summary

The study investigated the effectiveness of combined immunotherapy using anti-PD-1 and anti-GITR in treating non-small cell lung cancer (NSCLC) models. The researchers observed that the combination therapy significantly suppressed tumor growth in subcutaneous models and increased the presence of tumor-infiltrating T lymphocytes. They also observed a reduction in the population of regulatory T cells with the combination therapy. In addition, the combination therapy prevented the increased expression of PD-1 on CD8 T cells that was observed with anti-GITR monotherapy. However, in orthotopic models, the combination therapy was not effective in suppressing tumor growth. The researchers noted that the induction of cytotoxic CD8 T cells was only observed in the non-tumor-bearing lung, not in the tumor-bearing lung. The combination therapy also suppressed the accumulation of interstitial macrophages induced by the tumor burden. Overall, the study suggests that combined immunotherapy with anti-PD-1 and anti-GITR can effectively suppress tumor growth and modify the tumor microenvironment in NSCLC, although the efficacy may be location-dependent. Further research is needed to better understand the role of GITR-expressing cells in the tumor microenvironment and to develop optimal treatment strategies for NSCLC patients.

Asset Subtitle

Sheng Yan

Meta Tag

Speaker Sheng Yan

Topic Tumour Biology and Biomarkers - Immune Biology & Immunotherapy

Keywords

combined immunotherapy

anti-PD-1

anti-GITR

NSCLC models

tumor growth suppression

tumor-infiltrating T lymphocytes

regulatory T cells

PD-1 expression

cytotoxic CD8 T cells

tumor microenvironment